| abstract |
The disclosure relates to piperidin-purin-oxoindane derivative compounds of formulae (Ia) and (Ib), wherein the variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising these compounds which are suitable for the treatment of a disease or disorder that responds to the inhibition of molecular chaperone protein Hsp90 (Heat Shock Protein 90) chosen from inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant disease, scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. |